Erythrocyte/HEPG2-type glucose transporter is concentrated in cells of blood-tissue barriers

doi:10.1016/S0006-291X(05)81022-8

Biochemical and Biophysical Research Communications

Volume 173, Issue 1, 30 November 1990, Pages 67-73

https://doi.org/10.1016/S0006-291X(05)81022-8 Get rights and content

In search of possible diverse roles of glucose transporters(GT's), we examined whether any GT's are present in blood-tissue barriers where selective flow of glucose from blood to tissue cells is critically important. We found in rat that the erythrocyte/HepG2-type GT is localized in all the limiting plasma membranes known to serve as blood-tissue barriers, whether the barriers are endothelial type(brain, iris, inner retina, peripheral nerve) or epithelial type(choroid plexus, ciliary body, outer retina, peripheral nerve, placenta), except for plasma membranes in testis and thymus where no appreciable amount of the GT was found. The erythrocyte/HepG2-type GT may play a vital role for the entry of glucose into these firmly guarded tissues.

References (30)

BalyD.L. et al.
Biochim. Biophys. Acta
(1988)
KasaharaM. et al.
J. Boil. Chem.
(1977)
KasaharaM. et al.
Biochem. Biophys. Res. Commun.
(1985)
RaviolaG.
Exp. Eye Res.
(1977)
SaseS. et al.
Biochim. Biophys. Acta
(1982)
EzakiO. et al.
J. Biol. Chem.
(1986)
MuecklerM. et al.
Science
(1985)
HedigerM.A. et al.
Nature
(1987)
BellG.I. et al.
Diabetes Care
(1990)
ThorensB. et al.
Diabetes Care
(1990)

BetzA.L. et al.

ann. Rev. Physiol.

(1986)

FishmanR.A.

Cerebrospinal Fluid in Diseases of the Nervous System

(1980)

BöckP. et al.

Histochemie

(1971)

FaberJ.J. et al.

Placental Physiology

(1983)

DymM.

Anat. Rec.

(1973)

Cited by (154)

A transcriptomic and proteomic atlas of obesity and type 2 diabetes in cynomolgus monkeys
2023, Cell Reports
Obesity and type 2 diabetes (T2D) remain major global healthcare challenges, and developing therapeutics necessitates using nonhuman primate models. Here, we present a transcriptomic and proteomic atlas of all the major organs of cynomolgus monkeys with spontaneous obesity or T2D in comparison to healthy controls. Molecular changes occur predominantly in the adipose tissues of individuals with obesity, while extensive expression perturbations among T2D individuals are observed in many tissues such as the liver and kidney. Immune-response-related pathways are upregulated in obesity and T2D, whereas metabolism and mitochondrial pathways are downregulated. Moreover, we highlight some potential therapeutic targets, including SLC2A1 and PCSK1 in obesity as well as SLC30A8 and SLC2A2 in T2D. Our study provides a resource for exploring the complex molecular mechanism of obesity and T2D and developing therapies for these diseases, with limitations including lack of hypothalamus, isolated islets of Langerhans, longitudinal data, and body fat percentage.
Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells
2023, Journal of Advanced Research
Citation Excerpt :
Various transporters, including glucose transporters, mannose receptors, low-density lipoprotein receptors, transferrin receptors, and albumin-binding proteins, may serve as drug delivery portal [36]. Particularly, GLUT-1 is highly expressed in malignant cells and endothelial cells of tumor-vessels associated with neoplasms [37-40], where it mediates the transport of glucose as well as other similar substances [36,41]. Rg3 has a hydrophobic domain with a steroid structure in character with that of cholesterol which is the indispensable main ingredient of liposomes and a hydrophilic domain with two glucosyl groups.
Inherent or acquired resistance to paclitaxel (PTX) is a pivotal challenge for chemotherapy treatment of multidrug-resistant (MDR) breast cancer. Although various targeted drug-delivery systems, including nanoparticles and liposomes, are effective for MDR cancer treatment, their efficacy is restricted by immunosuppressive tumor microenvironment (TME).
Ginsenosides Rg3 was used to formulate unique Rg3-based liposomes loaded with PTX to establish Rg3-PTX-LPs, which were prepared by the thin-film hydration method. The stability of the Rg3-PTX-LPs was evaluated by particle size analysis through dynamic light scattering. The active targeting effect of Rg3-based liposomes was examined in an MCF-7/T xenograft model by an in a vivo imaging system. To evaluate the antitumor activity and mechanism of Rg3-PTX-LP, MTT, apoptosis assays, TAM regulation, and TME remodeling were performed in MCF-7/T cells in vitro and in vivo.
Rg3-PTX-LPs could specifically distribute to MCF7/T cancer cells and TME simultaneously, mainly through the recognition of GLUT-1. The drug resistance reversing capability and in vivo antitumor effect of Rg3-PTX-LPs were significantly improved compared with conventional cholesterol liposomes. The TME remodeling mechanisms of Rg3-PTX-LPs included inhibiting IL-6/STAT3/p-STAT3 pathway activation to repolarize protumor M2 macrophages to antitumor M1 phenotype, suppressing myeloid-derived suppressor cells (MDSCs), decreasing tumor-associated fibroblasts (TAFs) and collagen fibers in TME, and promoting apoptosis of tumor cells. Hence, through the dual effects of targeting tumor cells and TME remodeling, Rg3-PTX-LPs achieved a high tumor inhibition rate of 90.3%.
Our multifunctional Rg3-based liposome developed in the present study offered a promising strategy for rescuing the drug resistance tumor treatment.
Interaction of glucose sensing and leptin action in the brain
2020, Molecular Metabolism
Citation Excerpt :
The brain preferentially utilizes glucose as its energy source and all six isoforms of the facilitated glucose transporters are found in the brain [1]. Transport of glucose across the blood–brain barrier is mediated by endothelial glucose transporter-1 (GLUT1) [2], and cellular glucose uptake by astrocytes and neurons is primarily accomplished through GLUT1 and glucose transporter-3, respectively [3]. While it is traditionally believed that glucose enters neurons directly and undergoes glycolysis to form pyruvate and provide neuronal fuel, it is alternatively demonstrated that l-lactate serves as an energy substrate in neurons [4,5].
In response to energy abundant or deprived conditions, nutrients and hormones activate hypothalamic pathways to maintain energy and glucose homeostasis. The underlying CNS mechanisms, however, remain elusive in rodents and humans.
Here, we first discuss brain glucose sensing mechanisms in the presence of a rise or fall of plasma glucose levels, and highlight defects in hypothalamic glucose sensing disrupt in vivo glucose homeostasis in high-fat fed, obese, and/or diabetic conditions. Second, we discuss brain leptin signalling pathways that impact glucose homeostasis in glucose-deprived and excessed conditions, and propose that leptin enhances hypothalamic glucose sensing and restores glucose homeostasis in short-term high-fat fed and/or uncontrolled diabetic conditions.
In conclusion, we believe basic studies that investigate the interaction of glucose sensing and leptin action in the brain will address the translational impact of hypothalamic glucose sensing in diabetes and obesity.
Solute carrier transporters: the metabolic gatekeepers of immune cells
2020, Acta Pharmaceutica Sinica B
Citation Excerpt :
While GLUT6 was previously reported to mediate glucose uptake in endometrial cancer cells65, at least in macrophages, the lysosomally located GLUT6 is not a true glucose transporter, and its physiological roles in immune cells still need to be clarified further64. The information reviewed above glucose transporters involved in immune cells are summarized in Table 166–86,87-119. Glutamine is one of the most abundant amino acids in circulation.
Solute carrier (SLC) transporters meditate many essential physiological functions, including nutrient uptake, ion influx/efflux, and waste disposal. In its protective role against tumors and infections, the mammalian immune system coordinates complex signals to support the proliferation, differentiation, and effector function of individual cell subsets. Recent research in this area has yielded surprising findings on the roles of solute carrier transporters, which were discovered to regulate lymphocyte signaling and control their differentiation, function, and fate by modulating diverse metabolic pathways and balanced levels of different metabolites. In this review, we present current information mainly on glucose transporters, amino-acid transporters, and metal ion transporters, which are critically important for mediating immune cell homeostasis in many different pathological conditions.
Influence of glucose transporter 1 activity inhibition on neuroblastoma in vitro
2019, Gene
Citation Excerpt :
GLUTs are the main carriers of glucose uptake into cells. In the GLUT family, GLUT1 is responsible for primary glucose uptake and maintenance of basal glucose metabolism in cells (Takata et al., 1990). Previous studies showed that GLUT1 activity inhibition by WZB117 effectively reduced glycolysis and cell proliferation, induced cell-cycle arrest in laryngeal carcinoma and lung cancer (Zhou et al., 2009; Liu et al., 2012).
Most cancer cells predominantly produce their energy through a high rate of glycolysis in the presence of abundant oxygen. Glycolysis has become a target of anticancer strategies. Previous researches showed that glucose transporter 1 (GLUT1) inhibitor is effective as anticancer agents. This study assessed the effects of the selective GLUT1 inhibitor WZB117 on regulation of neuroblastoma (NB) cell line SH-SY5Y viability, cell cycle and glycolysis in vitro. SH-SY5Y cells were grown and treated with WZB117 for up to 72 h and then subjected to cell viability, qRT-PCR, Western blot and flow cytometry analysis. Level of ATP and LDH was also analyzed. The result showed that WZB117 treatment reduced tumor cells viability, downregulated level of GLUT1 protein. Moreover, WZB117 treatment arrested tumor cells at the G0–G1 phase of the cell cycle, induced tumor cells to undergo necrosis instead of apoptosis. In addition, WZB117 treatment downregulated the levels of intracellular ATP, LDH and glycolytic enzymes. Thus, WZB117-induced GLUT1 inhibition suppressed tumor cell growth, induced cell cycle arrest and reduced glycolysis metabolites in NB cells in vitro. This study suggested that GLUT1 can be used as a potential therapeutic target for NB.
Effect of maternal hypoglycaemia during gestation on materno-foetal nutrient transfer and embryo-foetal development: Evidence from experimental studies focused primarily on the rat
2018, Reproductive Toxicology
Glucose is the major energy substrate during embryogenesis and the embryo is dependent on glucose from the maternal circulation to ensure normal metabolism and growth. The placenta plays a key role in this nutrient transfer in mammals, both during embryogenesis and after the development of the chorio-allantoic placental circulation. Maternal hypoglycaemia is accompanied by foetal hypoglycaemia and maternal counter-regulatory measures including a priority to keep nutrients in the maternal circulation by restricting their transfer to the foetus. Concomitantly, the foetus initiates its own counter-regulatory attempt to secure nutrients for its development and survival. Despite these measures, there is a general decrease in nutrient transfer to the foetus, which may have severe consequences for foetal development such as malformations and delayed skeletal development.

View all citing articles on Scopus

View full text

Erythrocyte/HEPG2-type glucose transporter is concentrated in cells of blood-tissue barriers

Biochim. Biophys. Acta

J. Boil. Chem.

Biochem. Biophys. Res. Commun.

Exp. Eye Res.

Biochim. Biophys. Acta

J. Biol. Chem.

Science

Nature